Copyright © Inderes 2011 - present. All rights reserved.

OrganoClick

1,73 SEK

+6,48 %

Mindre end 1K følgere

ORGC

First North Stockholm

Chemicals

Basic Materials

+6,48 %
-1,15 %
-1,43 %
-7,26 %
-2,92 %
-36,98 %
-51,32 %
-82,13 %
-75,76 %

OrganoClick operates in environmental technology. The company offers specialized solutions based on fiber-based materials, where the company develops, produces and markets functional fiber chemistry. The products are mainly used in water-repellent fabrics and primarily in wood treatment to protect against fungal decay and fire. The company was founded in 2006 and has its headquarters in Täby.

Læs mere
Markedsværdi
189,76 mio. SEK
Aktieomsætning
440,65 t SEK
Omsætning
127,23 mio.
EBIT %
-7,75 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
12.2
2026

Årsrapport '25

6.5
2026

Delårsrapport Q1'26

20.5
2026

Generalforsamling '26

ViserAlle indholdstyper
Eksterne analyser

OrganoClick: Expecting to see early signs of recovery - ABG

* Q4e sales SEK 22m (21m), EBIT adj. SEK -5.5m (-6.9m) * We expect NW&FT to start showing early signs of recovery * Trading at '26e-'27e EV/Sales 2.2x-2.0x Q4 expectations For Q4, we estimate sales of SEK 22m, +2% y-o-y and -3% q-o-q (NW&FT: +7% y-o-...

OrganoClick
Eksterne analyser

OrganoClick: Cost savings to cushion volume headwinds - ABG

* Q3 soft, lower volumes from two major customers* We cut '26e-'27e sales and EBIT by 6% and SEK 6m, respectively* Expect volume recovery to take longer than initially projectedQ3 challenging, but cost savings aheadQ3 sales were lower than expected at...

OrganoClick

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

OrganoClick: Challenging Q3, but cost-cutting underway - ABG

* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.9m)* Lower volumes from two major customers due to timing effects* Cost savings program of ~SEK 14m announcedQ3 resultsSales came in lower than expected at SEK 22m (-18% vs. ABGSCe 27m), -22%...

OrganoClick
Eksterne analyser

OrganoClick: Expect gains in GCMP, pressure elsewhere - ABG

* Report out on 5 November* Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m)* GC&MP the bright spot, other segments under pressureQ3 expectationsQ3 marks the beginning of the second half of the year, which is typically weaker for OrganoClick (particularly...

OrganoClick
Eksterne analyser

OrganoClick - Near-term weakness in FW & NWFT to linger - ABG

Q2 figures pre-announced OrganoClick reported sales of SEK 30m (-23% y-o-y) and EBIT of -4.7m (-0.1m), in line with the 11 July profit warning. The miss was broad-based compared to estimates from our preview (pre-PW). NW&FT sales were -28% vs. ABGSCe...

OrganoClick
Eksterne analyser

OrganoClick: Q2 in line with PW, rights issue announced - ABG

Q2 figures in line with pre-announcement The Q2 figures were in line with the profit warning issued on 11 July, i.e. sales of SEK 30m (-23% y-o-y) and an EBIT of SEK -4.7m (-0.1m). FW sales were, as pre-announced in the PW, SEK 10.6m (-34% y-o-y). Sales...

OrganoClick
Eksterne analyser

Organoclick: Weak Q2 triggers PW - ABG

- Q2 sales SEK 30m, EBIT -4.7m (vs. ABGSCe 37m and -0.4m) - Costs savings of SEK 3m per year from Q4 - Cash balance SEK 2m in Q2, 10m loan booked in Q3 Sales and EBIT miss of SEK 7m and 4m vs. ABGSCe This morning, OrganoClick issued a PW and presented...

OrganoClick
Eksterne analyser

OrganoClick: NW&FT weakness to continue, set for better H2 - ABG

- Report out 18 July - Q2e: sales SEK 37m, -3% y-o-y, EBIT SEK -0.1m - Headwinds in NW&FT and FW, good momentum in GC&MP Q2 expectations We estimate Q2 sales of SEK 37m, -3% y-o-y and +6% q-o-q. We expect GC&MP will remain the growth driver (+9% y-o-...

OrganoClick
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.